Focal segmental glomerulosclerosis Stock Photos and Images
(6)See focal segmental glomerulosclerosis stock video clipsQuick filters:
Page 1 of 1
Focal segmental glomerulosclerosis Stock Photos and Images
FORT LEONARD WOOD, Mo. – Jozzalynn and Zackrie Duke receive their Covid-19 vaccination at General Leonard Wood Army Community Hospital Jan. 29. The siblings were organ donor recipients after being diagnosed with Focal Segmental Glomerulosclerosis, or FSGS, a disease in which scar tissue develops on the parts of the kidneys that filter waste from the blood. Stock Photohttps://www.alamy.com/licenses-and-pricing/?v=1https://www.alamy.com/fort-leonard-wood-mo-jozzalynn-and-zackrie-duke-receive-their-covid-19-vaccination-at-general-leonard-wood-army-community-hospital-jan-29-the-siblings-were-organ-donor-recipients-after-being-diagnosed-with-focal-segmental-glomerulosclerosis-or-fsgs-a-disease-in-which-scar-tissue-develops-on-the-parts-of-the-kidneys-that-filter-waste-from-the-blood-image447761788.htmlRM2H0D8MC–FORT LEONARD WOOD, Mo. – Jozzalynn and Zackrie Duke receive their Covid-19 vaccination at General Leonard Wood Army Community Hospital Jan. 29. The siblings were organ donor recipients after being diagnosed with Focal Segmental Glomerulosclerosis, or FSGS, a disease in which scar tissue develops on the parts of the kidneys that filter waste from the blood.
Sparsentan is a novel small-molecule candidate in Phase 3 development for the treatment of focal segmental glomerulosclerosis (FSGS). Stock Photohttps://www.alamy.com/licenses-and-pricing/?v=1https://www.alamy.com/sparsentan-is-a-novel-small-molecule-candidate-in-phase-3-development-for-the-treatment-of-focal-segmental-glomerulosclerosis-fsgs-image433292132.htmlRF2G4X4F0–Sparsentan is a novel small-molecule candidate in Phase 3 development for the treatment of focal segmental glomerulosclerosis (FSGS).
Ciclosporin (Cyclosporine) is a steroid-sparing immunosuppressant agent in the blood flow - isometric view 3d illustration Stock Photohttps://www.alamy.com/licenses-and-pricing/?v=1https://www.alamy.com/ciclosporin-cyclosporine-is-a-steroid-sparing-immunosuppressant-agent-in-the-blood-flow-isometric-view-3d-illustration-image556336859.htmlRF2R9399F–Ciclosporin (Cyclosporine) is a steroid-sparing immunosuppressant agent in the blood flow - isometric view 3d illustration
Sparsentan is a novel small-molecule candidate in Phase 3 development for the treatment of focal segmental glomerulosclerosis (FSGS). Stock Photohttps://www.alamy.com/licenses-and-pricing/?v=1https://www.alamy.com/sparsentan-is-a-novel-small-molecule-candidate-in-phase-3-development-for-the-treatment-of-focal-segmental-glomerulosclerosis-fsgs-image433292150.htmlRF2G4X4FJ–Sparsentan is a novel small-molecule candidate in Phase 3 development for the treatment of focal segmental glomerulosclerosis (FSGS).
Ciclosporin (Cyclosporine) is a steroid-sparing immunosuppressant agent in the blood flow - closeup view 3d illustration Stock Photohttps://www.alamy.com/licenses-and-pricing/?v=1https://www.alamy.com/ciclosporin-cyclosporine-is-a-steroid-sparing-immunosuppressant-agent-in-the-blood-flow-closeup-view-3d-illustration-image556336848.htmlRF2R93994–Ciclosporin (Cyclosporine) is a steroid-sparing immunosuppressant agent in the blood flow - closeup view 3d illustration
Sparsentan is a novel small-molecule candidate in Phase 3 development for the treatment of focal segmental glomerulosclerosis (FSGS). Stock Photohttps://www.alamy.com/licenses-and-pricing/?v=1https://www.alamy.com/sparsentan-is-a-novel-small-molecule-candidate-in-phase-3-development-for-the-treatment-of-focal-segmental-glomerulosclerosis-fsgs-image433292131.htmlRF2G4X4EY–Sparsentan is a novel small-molecule candidate in Phase 3 development for the treatment of focal segmental glomerulosclerosis (FSGS).
Search Results for Focal segmental glomerulosclerosis Stock Photos and Images (6)
Page 1 of 1